Compare American Financial Group Inc (AFG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? American Financial Group Inc trades at $144.65 (market cap $11.93B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11.1× American Financial Group Inc's market cap, and American Financial Group Inc pays a 2.45% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| AFG | VRTX | |
|---|---|---|
Market Cap | $11.93B | $132.79B |
Sector | Financials | Health |
52-Week High | $148.71 | $529.65 |
52-Week Low | $124.18 | $376.62 |
Enterprise Value | $12.31B | $126.92B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Financial Group (AFG) trades at $145.59, down 0.78% on the day, with strong technical momentum indicated by bullish moving averages. The company reported solid Q2 2026 earnings of $2.82 per share, beating estimates by 21.6%, driven by record property and casualty operating income. Recent news highlights strong underwriting margins and premium growth, while institutional activity shows mixed positioning with some funds increasing stakes and others reducing holdings.
AFG presents a compelling investment case with a reasonable P/E of 12.73 and strong ROE of 20.41%, supported by consistent dividend payments. The consensus price target of $159.00 suggests 9.2% upside potential. Key risks include competitive pressures in insurance markets and potential margin compression. Analyst sentiment is cautiously optimistic with 41% buy ratings, though the majority maintain hold recommendations awaiting clearer growth catalysts.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
